An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01678690 |
Recruitment Status :
Completed
First Posted : September 5, 2012
Last Update Posted : September 2, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Malignant Tumors | Drug: Gemcitabine HCl Oral Formulation | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Official Title: | An Open-Label, Exploratory, Limited Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors |
Study Start Date : | August 2012 |
Actual Primary Completion Date : | April 2014 |
Actual Study Completion Date : | April 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Gemcitabine HCl Oral Formulation
Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period
|
Drug: Gemcitabine HCl Oral Formulation
Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
Other Name: D07001-F4 |
- gemcitabine (dFdC) and difluorodeoxyuridine (dFdU) plasma concentration and gemcitabine triphosphate (dFdCTP) concentration in PBMC [ Time Frame: Day 1-5 ]
- the proportion of subjects experiencing adverse events all grades, change from baseline in clinical laboratory test results, vital sign measurements, and physical examination findings [ Time Frame: Day 1-8 (+/- 1) days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female subjects aged 18 years and older.
- Signed and dated informed consent form.
- Subjects with malignancies with histological or pathologic confirmation and who are clinically stable.
- History of treatment with at least 1 cytotoxic chemotherapy regimen for the current malignancy.
- If the subject has received cytotoxic chemotherapy within the past 14 days, the subject is beyond the nadir of white blood cell and platelet counts.
- At least 28 days have elapsed since the subject's prior radiotherapy or any major surgery (excluding diagnostic biopsy or venous access device placement).
- World Health Organization (WHO) performance status 0 to 2
- Subject has an ANC ≥1500 cells/mm³, platelet count ≥ 100,000 cells/mm³, and hemoglobin ≥ 9 g/dL.
- Subject has adequate liver function demonstrated by transaminases within normal limits (aspartate transaminase and alanine transaminase), total bilirubin ≤ 1.5 mg/dL (unless due to Gilbert's syndrome), albumin ≥ 2.5 g/dL, international normalized ratio [INR] < 1.5).
- Subject has adequate renal function: serum creatinine ≤ 1.5 x upper limit of normal.
- Subject has a life expectancy >24 weeks.
- If a women of child-bearing potential, subject has a negative pregnancy test and is not breast-feeding.
- If a women of child-bearing potential, subject is using a medically acceptable form of birth control prior to screening and for the duration of their study participation and for 1 month after the end of the study.
- Subject is willing to comply with protocol-required visit schedule and visit requirements and provide written informed consent.
Exclusion Criteria:
- Subject has rapidly progressive disease or rapid clinical deterioration as assessed by the Investigator.
- Subject is receiving full-dose (therapeutic) anticoagulation therapy.
- Subject is receiving concomitant radiotherapy.
- Subject is intolerant or allergic or has a known hypersensitivity to gemcitabine.
- Subject has clinically significant cardiovascular disease (for example: uncontrolled hypertension, unstable angina, congestive heart failure, or New York Heart Association Grade 2 or greater).
- Subject has uncontrolled serious cardiac arrhythmia.
- Subject has known active brain metastases, or any leptomeningeal metastases.
- Subject has a history of drug or alcohol abuse within last year.
- Subject has documented cerebrovascular disease.
- Subject has a seizure disorder not controlled on medication.
- Subject received an investigational agent within 30 days of screening.
- Subject received systemic treatment for infection within 14 days of screening.
- Subject has known human immunodeficiency virus infection or viral hepatitis.
- Subject has any other serious medical condition that, in the investigator's medical opinion, would preclude safe participation in a clinical trial.
- Subject has gastrointestinal disease or prior gastrointestinal surgery that may interfere with adequate oral therapy absorption.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01678690
United States, Georgia | |
Georgia Regents University- Cancer Center | |
Augusta, Georgia, United States, 30912 | |
United States, Ohio | |
Gabrail Cancer Center Research | |
Canton, Ohio, United States, 44718 | |
Gabrail Cancer Center Research | |
Dover, Ohio, United States, 44622 | |
Taiwan | |
National Taiwan University Hospital | |
Taipei, Taiwan, 10048 |
Principal Investigator: | Nashat Y. Gabrail, MD | Gabrail Cancer Center Research | |
Principal Investigator: | Sharad Ghamande, MD | Augusta University | |
Principal Investigator: | Chia-Chi Lin, MD | National Taiwan University Hospital |
Responsible Party: | InnoPharmax Inc. |
ClinicalTrials.gov Identifier: | NCT01678690 |
Other Study ID Numbers: |
HR-11-001 |
First Posted: | September 5, 2012 Key Record Dates |
Last Update Posted: | September 2, 2016 |
Last Verified: | August 2016 |
Neoplasms Gemcitabine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |